Breast Imaging

What Imaging Is Best for Breast Cancer Screening in a Young, High-Risk Pregnant Patient?

·
What Imaging Is Best for Breast Cancer Screening in a Young, High-Risk Pregnant Patient?

A 23-year-old G1P0 presents for her 16-week obstetric visit. She is anxious about her breast cancer risk, noting her mother was diagnosed at age 32 and she carries a known BRCA1 mutation. While routine screening is not typically performed during pregnancy, her high-risk status complicates the decision. The primary care physician or OB/GYN must now determine the safest and most effective imaging strategy to screen for an occult malignancy without harming the fetus. This article provides a detailed clinical workflow for this specific scenario, grounded in the American College of Radiology (ACR) Appropriateness Criteria, which rate breast ultrasound as `May be appropriate` as a potential screening tool.

Who Fits This Clinical Scenario?

This guidance applies to a very specific patient population: pregnant females under the age of 25 who are considered to have a higher-than-average risk for developing breast cancer. This is a screening scenario, meaning the patient has no symptoms, such as a palpable lump, focal pain, or suspicious nipple discharge.

Inclusion Criteria:

  • Patient is confirmed to be pregnant.
  • Patient is less than 25 years old.
  • Patient has no clinical signs or symptoms of breast disease.
  • Patient has a documented higher-than-average risk. This typically includes individuals with a known pathogenic genetic mutation (e.g., BRCA1, BRCA2), a calculated lifetime risk >20% based on models like Tyrer-Cuzick, or a history of chest wall radiation between ages 10 and 30.

Exclusion Criteria (These patients require a different workflow):

  • Symptomatic Patients: A pregnant patient with a palpable mass or focal pain falls under a diagnostic workup, not screening. See the ACR variant for focal pain or palpable breast mass in a pregnant female under 30.
  • Older Pregnant Patients: Pregnant patients aged 25 or older with high risk are addressed in a separate ACR variant, which may have different imaging considerations.
  • Average-Risk Patients: Pregnant individuals without high-risk factors are not candidates for breast cancer screening during pregnancy.

What Diagnoses Are You Working Up in This Scenario?

Because this is a screening scenario in a high-risk individual, the primary goal is the early detection of an otherwise occult breast cancer. However, any imaging performed will also need to differentiate potential malignancies from the extensive physiologic and benign changes that occur in the breast during pregnancy.

Breast Cancer: The principal target. While rare in this age group, the risk is significantly elevated in patients with genetic mutations like BRCA1. Pregnancy-associated breast cancer (PABC) can be more aggressive, making early detection in a high-risk patient a critical consideration.

Lactating Adenoma: A benign, well-circumscribed tumor that is hormonally responsive and often arises during pregnancy or lactation. On imaging, it can sometimes mimic a malignancy, appearing as a solid, mobile mass, but typically has benign features on ultrasound.

Galactocele: A milk-filled cyst caused by a blocked duct. It is the most common benign breast lesion during pregnancy and lactation. On ultrasound, it can have a variable appearance, from a simple cyst to a complex cystic and solid mass, which can occasionally raise suspicion.

Fibroadenoma: A very common benign breast tumor in young women. Existing fibroadenomas can grow rapidly during pregnancy due to hormonal stimulation, potentially becoming palpable or more prominent on imaging. Differentiating a growing fibroadenoma from a new malignancy is a key task.

Why Is Breast Ultrasound the Recommended Study for This Presentation?

For a high-risk pregnant patient under 25, the ACR rates breast ultrasound (US) as `May be appropriate`. This rating reflects a careful balance of diagnostic utility, patient risk, and fetal safety. It is not rated higher because routine screening of all high-risk pregnant patients is not established policy; the decision is individualized.

The primary rationale for choosing ultrasound is its complete lack of ionizing radiation (0 mSv), making it unequivocally safe for the fetus at any gestational age. Furthermore, pregnancy induces significant physiologic changes in the breasts, including increased glandular proliferation and density. This increased density severely limits the sensitivity of mammography. Ultrasound, however, excels in evaluating dense breast tissue, allowing for clear visualization of both normal glandular architecture and potential focal lesions.

Why are other studies rated lower for this specific scenario?

  • Mammography and Digital Breast Tomosynthesis (DBT): Both are rated `Usually not appropriate`. The main reasons are the use of ionizing radiation (☢☢ 0.1-1mSv), which, while low and targeted away from the fetus with abdominal shielding, is avoided when a non-ionizing alternative exists. Additionally, their diagnostic performance is substantially reduced by the increased breast density of pregnancy.
  • MRI Breast Without and With IV Contrast: This is also rated `Usually not appropriate` for screening in this context. The primary concern is the use of gadolinium-based contrast agents. Gadolinium is known to cross the placenta, enter the fetal circulation, and be excreted into the amniotic fluid, with unknown long-term consequences for the developing fetus. Therefore, contrast-enhanced studies are avoided during pregnancy unless the potential benefit unequivocally outweighs the theoretical risk. MRI without contrast has very limited utility for breast cancer screening.

In summary, ultrasound provides a safe and effective initial screening modality for this unique patient population, capable of detecting suspicious solid masses that would warrant further investigation while avoiding fetal exposure to radiation or contrast agents.

What’s Next After Breast Ultrasound? Downstream Workflow

The results of the screening breast ultrasound, interpreted using the BI-RADS classification system, will dictate the subsequent clinical pathway. The goal is to provide reassurance when possible and to efficiently diagnose any suspicious findings while maintaining maternal and fetal safety.

If the Ultrasound is Negative (BI-RADS 1) or Benign (BI-RADS 2):

No suspicious findings are identified. The patient can be reassured. No further imaging is typically required during the pregnancy. She should resume her high-risk screening protocol (which often includes annual breast MRI) after delivery and cessation of lactation.

If the Ultrasound is Probably Benign (BI-RADS 3):

This indicates a finding with a very low likelihood of malignancy (<2%). The standard recommendation is short-interval follow-up. In a pregnant patient, this may involve a repeat targeted ultrasound in 3-6 months, even during the pregnancy, or deferring the follow-up until the immediate postpartum period. The decision should be made in consultation with the patient and a breast imaging specialist.

If the Ultrasound is Suspicious or Highly Suggestive of Malignancy (BI-RADS 4 or 5):

A tissue diagnosis is mandatory. The next step is an ultrasound-guided core needle biopsy. This procedure is safe to perform during pregnancy, using local anesthesia, and is the standard of care for diagnosing a suspicious breast mass. If malignancy is confirmed, the patient must be referred immediately to a multidisciplinary team including a breast surgeon, medical oncologist, and maternal-fetal medicine specialist to coordinate cancer treatment during pregnancy.

Pitfalls to Avoid (and When to Get Help)

Navigating breast imaging in a young, high-risk pregnant patient requires careful consideration to avoid common errors.

  • Pitfall 1: Dismissing Risk Due to Age. Do not let the patient’s young age overshadow a significant risk factor like a BRCA mutation. High-risk is high-risk, and pregnancy does not confer protection.
  • Pitfall 2: Normalization of Changes. Avoid attributing all breast changes solely to pregnancy without an objective evaluation. While most changes are physiologic, a new, persistent, or focal finding in a high-risk patient warrants an imaging workup.
  • Pitfall 3: Delaying Biopsy. If an ultrasound reveals a BI-RADS 4 or 5 lesion, do not postpone a biopsy until after delivery. A delay in diagnosis can negatively impact prognosis, and ultrasound-guided biopsy is a safe and well-established procedure during pregnancy.

If a suspicious lesion (BI-RADS 4 or 5) is identified on ultrasound, the case should be immediately escalated for discussion with a breast radiologist and a referral made to a breast surgeon for biopsy planning and multidisciplinary consultation.

Related ACR Topics and Tools

This article covers one specific variant within the broader topic of breast imaging in pregnant and lactating patients. For a comprehensive overview of all related scenarios, from palpable masses to nipple discharge, please consult our parent guide. For additional decision support, the following GigHz resources are available:

Frequently Asked Questions

Why not just wait until after delivery to screen a high-risk patient?

The decision to screen during pregnancy is individualized and based on the level of risk. For very high-risk patients (e.g., BRCA carriers), a cancer diagnosed during pregnancy can be more aggressive. Delaying screening by 9+ months could potentially allow an early-stage cancer to advance, leading to a worse prognosis. The potential benefit of early detection may outweigh the complexities of imaging during pregnancy.

What defines ‘higher-than-average risk’ in a patient under 25?

In this age group, ‘higher-than-average risk’ is typically defined by very strong risk factors. This includes known pathogenic mutations in genes like BRCA1 or BRCA2, a personal history of mantle radiation for lymphoma between ages 10-30, or a calculated lifetime risk exceeding 20% on risk assessment models, often driven by a profound family history of early-onset breast cancer.

If the screening ultrasound is suspicious, is a biopsy safe during pregnancy?

Yes. An ultrasound-guided core needle biopsy is the standard procedure for diagnosing a suspicious breast mass and is considered safe for both the mother and fetus during pregnancy. It is performed with local anesthetic (like lidocaine), which has a long history of safe use in pregnancy, and avoids general anesthesia or significant procedural stress.

Why is breast ultrasound rated ‘May be appropriate’ instead of ‘Usually appropriate’?

The ‘May be appropriate’ rating reflects the lack of consensus on routine screening for all high-risk pregnant women. The decision is highly dependent on the specific patient’s risk profile, anxiety level, and a shared decision-making process with her clinical team. It indicates that ultrasound is a reasonable option to consider in this context, but it is not a universally mandated screening test for every patient who fits the criteria.

Is there any role for breast MRI without contrast in this scenario?

According to the ACR, non-contrast breast MRI is rated ‘Usually not appropriate’ for screening. While it avoids gadolinium, its sensitivity for detecting breast cancer is significantly lower than that of a contrast-enhanced MRI and is not considered an effective screening tool on its own. Its utility is very limited in this specific clinical context.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026